Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU) is a regenerative and aging-related cellular medicine company whose news flow reflects developments across placental-derived biomaterial products, cell therapies, financing, and regulatory milestones. As a Nasdaq-listed issuer, Celularity regularly reports corporate updates, clinical data, partnerships, and capital markets transactions that are relevant to investors and observers of the regenerative medicine and longevity sectors.
News about Celularity often covers its advanced biomaterial products and wound care franchise, including updates on Biovance and Biovance 3L human amniotic membrane allografts and related reimbursement and coverage policies. The company has commented on Centers for Medicare & Medicaid Services decisions affecting skin substitute products and has highlighted real-world evidence from clinical use of its wound care products. These items can influence perceptions of the company’s commercial trajectory in chronic wound management.
Another key category of Celularity news involves its placenta-derived cell therapy programs, such as PDA-002. The company has announced peer-reviewed Phase 2 clinical trial results in diabetic foot ulcers complicated by peripheral artery disease and has discussed how state-level laws, particularly in Florida, may enable physician-directed use of certain stem cell therapies in orthopedics, wound care, and pain management. Such updates provide insight into the clinical and regulatory landscape for its investigational products.
Celularity’s press releases also address strategic partnerships and corporate structure. Examples include collaborations with Fountain Life in longevity-focused centers and with DefEYE, Inc. in ophthalmic biologics, as well as internal restructuring into distinct operating subsidiaries. In addition, the company reports on financings, debt restructuring, Nasdaq listing rule matters, and preferred stock or warrant issuances. For readers tracking CELU, this news page aggregates these developments so they can follow how Celularity’s placental-derived platform, commercial units, and capital structure evolve over time.
Celularity Inc. (Nasdaq:CELU) secured approximately $138 million in funding through a merger with GX Acquisition Corp. and a PIPE investment. The company expanded its Phase 1 trial for CYNK-001 to include difficult-to-treat patients with acute myeloid leukemia. Additionally, the FDA granted Orphan Drug Designation for CYNK-001. Celularity formed strategic partnerships with Imugene Ltd and Palantir to enhance its therapeutic developments and data analysis capabilities. However, second quarter revenues decreased by $0.3 million, with a net loss of $64.5 million.
Imugene Ltd and Celularity Inc have entered a research collaboration to explore the combination of Imugene’s CF33-CD19 oncolytic virus with Celularity’s CD19-targeting CAR T-cell therapy, CyCART-19, aimed at treating solid tumors. The partnership plans to initiate nonclinical studies in 2021, leveraging Celularity’s advanced T-cell therapy, which demonstrates sustained efficacy against tumors. The collaboration could potentially expand CAR T-cell therapy's application beyond hematological malignancies, enhancing treatment options for solid tumors. The first clinical trial is anticipated to start in 2022.
Celularity, Inc. announced the successful closing of its merger with GX Acquisition Corp., with gross proceeds of approximately $138 million. Common stock will trade on Nasdaq as CELU starting July 19, 2021. The company aims to innovate cancer treatment through placental-derived cell therapies, having multiple clinical programs for acute myeloid leukemia and glioblastoma. Notable partnerships with Palantir and Arthrex are also anticipated to enhance growth and revenue.